The test is now ordered by breast surgeons or radiation oncologists in more than 85% of the top 50 U.S. cancer centers. “DCISionRT is becoming the standard of care for physicians and patients ...
Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first independent validation of AidaBreasttm, a novel multi-omic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback